We walked into a mess of all the biologics, the expensive biologics that again are amazing, that are about to come off patent in the next 10 years. Only 10% [of biologics] have a biosimilar in development. It should be 30% or 40% or more. These reforms have tremendous implications for everyone and every stakeholder in health care. I want to thank the staff at the fda. They've been wanting to do this for a long time. (15:09–15:18)
CLAIM
Asserts that only 10% of biologics have a biosimilar in development, which should be higher.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
_(cropped).png)